Tekla Capital Management as of June 30, 2014
Portfolio Holdings for Tekla Capital Management
Tekla Capital Management holds 64 positions in its portfolio as reported in the June 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Gilead Sciences (GILD) | 11.4 | $125M | 1.5M | 82.91 | |
| Celgene Corporation | 7.4 | $81M | 944k | 85.88 | |
| Biogen Idec (BIIB) | 5.0 | $55M | 174k | 315.31 | |
| Regeneron Pharmaceuticals (REGN) | 5.0 | $55M | 194k | 282.47 | |
| Amgen (AMGN) | 4.9 | $53M | 450k | 118.37 | |
| Alexion Pharmaceuticals | 4.8 | $53M | 336k | 156.25 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 4.7 | $51M | 541k | 94.68 | |
| Actavis | 4.2 | $46M | 206k | 223.05 | |
| Incyte Corporation (INCY) | 4.0 | $43M | 768k | 56.44 | |
| Mylan | 3.1 | $34M | 652k | 51.56 | |
| Shire | 2.7 | $29M | 123k | 235.49 | |
| Allergan | 2.4 | $27M | 157k | 169.22 | |
| BioMarin Pharmaceutical (BMRN) | 2.4 | $26M | 421k | 62.21 | |
| Akorn | 2.1 | $23M | 699k | 33.25 | |
| Aetna | 1.8 | $20M | 248k | 81.08 | |
| Illumina (ILMN) | 1.7 | $19M | 104k | 178.54 | |
| Cubist Pharmaceuticals | 1.7 | $18M | 264k | 69.82 | |
| iShares NASDAQ Biotechnology Index (IBB) | 1.5 | $17M | 65k | 257.03 | |
| Teva Pharmaceutical Industries (TEVA) | 1.5 | $16M | 312k | 52.42 | |
| Jazz Pharmaceuticals (JAZZ) | 1.3 | $14M | 96k | 147.01 | |
| Celladon | 1.2 | $13M | 971k | 13.62 | |
| Alkermes (ALKS) | 1.2 | $13M | 256k | 50.33 | |
| McKesson Corporation (MCK) | 1.2 | $13M | 68k | 186.22 | |
| Neurocrine Biosciences (NBIX) | 1.1 | $12M | 791k | 14.84 | |
| Ironwood Pharmaceuticals (IRWD) | 1.1 | $12M | 768k | 15.33 | |
| Forest Laboratories | 1.0 | $11M | 110k | 99.00 | |
| Heron Therapeutics (HRTX) | 1.0 | $11M | 874k | 12.32 | |
| Alere | 1.0 | $11M | 287k | 37.42 | |
| Sagent Pharmaceuticals | 1.0 | $11M | 405k | 25.86 | |
| Impax Laboratories | 0.9 | $10M | 345k | 29.99 | |
| Catamaran | 0.9 | $10M | 231k | 44.16 | |
| Pfizer (PFE) | 0.9 | $9.9M | 335k | 29.68 | |
| Bristol Myers Squibb (BMY) | 0.9 | $9.8M | 203k | 48.51 | |
| Molina Healthcare (MOH) | 0.9 | $9.5M | 213k | 44.63 | |
| Perrigo Company (PRGO) | 0.8 | $9.2M | 63k | 145.76 | |
| Endo International (ENDPQ) | 0.8 | $8.8M | 126k | 70.02 | |
| Infinity Pharmaceuticals (INFIQ) | 0.8 | $8.7M | 681k | 12.74 | |
| Verastem | 0.8 | $8.3M | 919k | 9.06 | |
| PerkinElmer (RVTY) | 0.7 | $7.8M | 166k | 46.84 | |
| Acorda Therapeutics | 0.7 | $7.6M | 226k | 33.71 | |
| IDEXX Laboratories (IDXX) | 0.7 | $7.5M | 56k | 133.56 | |
| Thermo Fisher Scientific (TMO) | 0.7 | $7.0M | 60k | 118.00 | |
| UnitedHealth (UNH) | 0.6 | $6.8M | 83k | 81.74 | |
| Accuray Incorporated (ARAY) | 0.6 | $6.4M | 732k | 8.80 | |
| BioDelivery Sciences International | 0.6 | $6.1M | 502k | 12.07 | |
| Intellipharmaceuticsintl Inc C | 0.5 | $5.3M | 1.4M | 3.81 | |
| Centene Corporation (CNC) | 0.4 | $4.5M | 60k | 75.62 | |
| Momenta Pharmaceuticals | 0.4 | $4.3M | 354k | 12.08 | |
| Merrimack Pharmaceuticals In | 0.4 | $4.1M | 568k | 7.29 | |
| Alnylam Pharmaceuticals (ALNY) | 0.4 | $3.9M | 62k | 63.17 | |
| NPS Pharmaceuticals | 0.2 | $2.7M | 83k | 33.05 | |
| Intermune Inc note 2.500% 9/1 | 0.2 | $2.7M | 1.8M | 1.50 | |
| Epizyme | 0.2 | $2.2M | 70k | 31.11 | |
| Bluebird Bio (BLUE) | 0.2 | $2.1M | 55k | 38.57 | |
| Ptc Therapeutics I (PTCT) | 0.2 | $2.1M | 79k | 26.14 | |
| Clovis Oncology | 0.2 | $2.0M | 47k | 41.40 | |
| Merrimack Pharmaceuticals In note 4.500% 7/1 | 0.2 | $2.0M | 1.5M | 1.32 | |
| Sangamo Biosciences (SGMO) | 0.2 | $1.8M | 120k | 15.27 | |
| Kythera Biopharmaceuticals I | 0.2 | $1.9M | 49k | 38.37 | |
| Amarin Corporation (AMRN) | 0.2 | $1.8M | 1.0M | 1.76 | |
| Mei Pharma | 0.1 | $1.5M | 244k | 6.34 | |
| Macrogenics (MGNX) | 0.1 | $692k | 32k | 21.72 | |
| OncoGenex Pharmaceuticals | 0.0 | $422k | 113k | 3.73 | |
| Aegerion Pharmaceuticals | 0.0 | $1.0k | 20.00 | 50.00 |
